[Aptamer therapeutics].
Miyakawa
Shin
S
info@ribomic.com
Fujiwara
Masatoshi
M
Nakamura
Yoshikazu
Y
D000818:Animals; D052157:Aptamers, Nucleotide / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015195:Drug Design; D004355:Drug Stability; D039562:Eukaryotic Initiation Factor-4F / Q000235:genetics; D018390:Gene Targeting; D006801:Humans; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use; D010750:Phosphoproteins; D016601:RNA-Binding Proteins; D052156:SELEX Aptamer Technique; D042461:Vascular Endothelial Growth Factor A; D000097796:Nucleolin
D052157:Aptamers, Nucleotide; D039562:Eukaryotic Initiation Factor-4F; D009838:Oligodeoxyribonucleotides; D010750:Phosphoproteins; D016601:RNA-Binding Proteins; D042461:Vascular Endothelial Growth Factor A; D000097796:Nucleolin; C513936:AGRO 100; C467484:VEGFA protein, human; C495058:pegaptanib